Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCZKN7)

Drug Name
4-Phenylbutyrohydroxamic acid Drug Info
Synonyms
N-Hydroxy-4-phenylbutanamide; 32153-46-1; NSC131300; UNII-QX182FOM5S; QX182FOM5S; 4-phenylbutanehydroxamic acid; CHEMBL55895; 4-Phenylbutyrohydroxamic acid; Benzenebutanamide, N-hydroxy-; NSC 131300; AC1Q7DIW; AC1L5RDX; Phenylbutyrylhydroxamic Acid; AC1Q5QD1; N-Hydroxy-4-phenyl-butyramide; 4-Phenylbutyryl hydroxamic acid; SCHEMBL1350853; CTK4G8310; DTXSID60185943; MolPort-011-492-164; UPHXPXYRKPCXHK-UHFFFAOYSA-N; ZINC4962622; STL301752; BDBM50015142; AKOS009266186; MCULE-9765156954; NSC-131300; NE28489; BCB03_000829; EN300-68596
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
279980
CAS Number
CAS 32153-46-1
TTD Drug ID
DMCZKN7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Histone deacetylase 6 (HDAC6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Citarinostat DMQLODU Multiple myeloma 2A83 Phase 1 [2]
KA2507 DMW0H9Y Solid tumour/cancer 2A00-2F9Z Phase 1 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 8 (HDAC8)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NBM-BMX DM5OWXA Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 2 (HDAC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [5]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase (HDAC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [6]
Sodium phenylbutyrate DMXLBCQ Spinal muscular atrophy 8B61 Approved [7]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [2]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [8]
Pracinostat DMTD7AB Acute myeloid leukaemia 2A60 Phase 3 [9]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [10]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [2]
CMS-024-02 DMC4X7L Solid tumour/cancer 2A00-2F9Z Phase 3 [11]
Abexinostat DM91LGU Follicular lymphoma 2A80 Phase 3 [12]
PDX-101 DM6OC53 Plasma cell myeloma 2A83.1 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Histone deacetylase 1 (HDAC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vorinostat DMWMPD4 Adult acute monocytic leukemia Approved [14]
Romidepsin DMT5GNL Cutaneous T-cell lymphoma 2B01 Approved [15]
Panobinostat DM58WKG Chronic graft versus host disease Approved [14]
HBI-8000 DMDWYUN Non-small-cell lung cancer 2C25.Y Registered [13]
ITF2357 DMFZBNE Duchenne dystrophy 8C70 Phase 3 [16]
NVP-LAQ824 DM8JWNA Mood disorder 6A60-6E23 Phase 3 [17]
SNDX-275 DMH7W9X Breast cancer 2C60-2C65 Phase 3 [10]
Phenylbutyrate DMBHPDW Urea cycle disorder 5C50.A Phase 2 [18]
MGCD-0103 DM726HX Non-small-cell lung cancer 2C25.Y Phase 2 [14]
Resminostat DMNE1FR Hepatocellular carcinoma 2C12.02 Phase 2 [19]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase (HDAC) TTBH0VX NOUNIPROTAC Inhibitor [1]
Histone deacetylase 1 (HDAC1) TT6R7JZ HDAC1_HUMAN Inhibitor [1]
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [1]
Histone deacetylase 6 (HDAC6) TT5ZKDI HDAC6_HUMAN Inhibitor [1]
Histone deacetylase 8 (HDAC8) TTT6LFV HDAC8_HUMAN Inhibitor [1]

References

1 Chemical phylogenetics of histone deacetylases. Nat Chem Biol. 2010 Mar;6(3):238-243.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.
4 Clinical pipeline report, company report or official report of NatureWise Biotech & Medicals.
5 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
6 Transcription-independent heritability of induced histone modifications in the mouse preimplantation embryo. PLoS One. 2009 Jun 30;4(6):e6086.
7 Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets. 2010 Nov;11(11):1430-8.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8365).
10 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
11 US patent application no. 2012,0302,505, Cyclodextrin-based polymers for therapeutic delivery.
12 Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia. Invest New Drugs. 2015 Apr;33(2):423-31.
13 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
14 Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov. 2009 Sep;8(9):724-32.
15 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
16 Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9.
17 NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 1;102(7):2615-22.
18 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
19 2011 Pipeline of 4SC AG.